TY - JOUR T1 - Analysis of 200,000 exome-sequenced UK Biobank subjects fails to identify genes influencing probability of developing a mood disorder resulting in psychiatric referral JF - medRxiv DO - 10.1101/2021.01.07.20249042 SP - 2021.01.07.20249042 AU - David Curtis Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/14/2021.01.07.20249042.abstract N2 - Background Depression is moderately heritable but there is no common genetic variant which has a major effect on susceptibility. A previous analysis of 50,000 subjects failed to implicate any genes or sets of genes associated with risk of affective disorder requiring specialist treatment. A large exome-sequenced dataset is now available.Methods Data from 200,632 exome-sequenced UK Biobank participants was analysed. Subjects were treated as cases if they had reported having seen a psychiatrist for “nerves, anxiety, tension or depression”. Gene-wise weighted burden analysis was performed to see if there were any genes or sets of genes for which there was an excess of rare, functional variants in cases.Results There were 22,886 cases and 176,486 controls. There were 22,642 informative genes but no gene or gene set produced a statistically significant result after correction for multiple testing. None of the genes or gene sets with the lowest p values appeared to be a biologically plausible candidate.Limitations The phenotype is based on self-report and the cases are likely to somewhat heterogeneous. Likewise, it is expected that some of the subjects classed as controls will in fact have suffered from depression or some other psychiatric diagnosis.Conclusions The results conform exactly with the expectation under the null hypothesis. It seems unlikely that the use of common, poorly defined phenotypes will produce useful advances in understanding genetic contributions to affective disorder and it might be preferable to focus instead on obtaining large exome-sequenced samples of conditions such as bipolar 1 disorder and severe, recurrent depression.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank had obtained ethics approval from the North West Multi-centre Research Ethics Committee which covers the UK (approval number: 11/NW/0382) and had obtained informed consent from all participants. The UK Biobank approved an application for use of the data (ID 51119) and ethics approval for the analyses was obtained from the UCL Research Ethics Committee (11527/001).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data is available on application to UK Biobank. Detailed results with variant counts cannot be made available because they might be used for subject identification. ER -